10-K/APeriod: FY2009

REGENERON PHARMACEUTICALS, INC. Annual Report (Amendment), Year Ended Dec 31, 2009

Filed June 2, 2010For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an amendment to its 2009 Annual Report (10-K/A) on June 1, 2010. This filing primarily provides access to the company's exhibits and financial statement schedules. For investors, the most critical information would be found in the detailed financial statements themselves, which are typically included or referenced in the 10-K, and the exhibits which may contain material agreements, contracts, and other documents that provide deeper insight into the company's operations, strategic partnerships, and potential liabilities or opportunities. While this specific amendment focuses on the supplementary sections, a thorough investor analysis would require reviewing the complete 10-K filing for the period ending December 30, 2009. This would include management's discussion and analysis of financial condition and results of operations, risk factors, and details on the company's product pipeline and development stage. Investors should look for information regarding revenue generation, research and development expenditures, clinical trial progress, and any significant collaborations or licensing agreements that could impact future growth.

Financial Highlights

39 data points
Beta

Revenue

$379.27M

99.6% Gross Margin

Net Income

-$67.83M

-17.9% Net Margin

EPS (Diluted)

$-0.85

Total Assets

$741.20M

Cash & Equivalents

$207.07M

Free Cash Flow

-$69.94M

Financial Statements
Beta
Revenue$379.27M
Cost of Revenue$1.69M
Gross Profit$377.58M
R&D Expenses$398.76M
SG&A Expenses$52.92M
Operating Expenses$453.37M
Operating Income-$74.10M
Interest Expense$2.34M
Net Income-$67.83M
EPS (Basic)$-0.85

Key Highlights

  • 1The filing is an amendment (10-K/A) to the 2009 Annual Report, primarily containing exhibits and financial statement schedules.
  • 2The period ending for the financial data is December 30, 2009.
  • 3Investors should consult the full 10-K for comprehensive financial data and management discussion.
  • 4Exhibits are a key component, potentially revealing material contracts and agreements.
  • 5Understanding the financial statements and associated disclosures is crucial for assessing Regeneron's performance.
  • 6The filing relates to the operational and financial status of Regeneron Pharmaceuticals, Inc. as of the end of 2009.

Frequently Asked Questions

This 10-K/A filing is an amendment to Regeneron Pharmaceuticals' 2009 Annual Report. Its primary purpose, as indicated by Item 15, is to provide access to the company's exhibits and financial statement schedules, which supplement the main body of the original 10-K.

This amendment itself does not contain the detailed financial statements or management discussion. Investors will need to refer to the original 10-K filing for the period ending December 30, 2009, to find the complete financial statements (balance sheets, income statements, cash flow statements) and the Management's Discussion and Analysis (MD&A) of financial condition and results of operations.

Exhibits can include critical documents such as material contracts, license agreements, debt instruments, and other legal or business agreements that provide substantial insight into the company's strategic relationships, revenue streams, potential liabilities, and operational framework. Financial statement schedules offer a more detailed breakdown of certain financial statement line items.

Information regarding the product pipeline and research and development activities would typically be detailed in the main sections of the original 10-K filing, specifically within the 'Business' section and 'Management's Discussion and Analysis of Financial Condition and Results of Operations'. This amendment primarily focuses on the supplementary disclosure items.